The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
Castration resistant prostate cancer patients treated with enzalutamide may develop resistance to the drug. Here, the authors report that monoamine oxidase-A expression is increased in these resistant tumors and that the antidepressants phenelzine/clorgyline can reverse such resistance to further su...
Enregistré dans:
Auteurs principaux: | Keliang Wang, Jie Luo, Shuyuan Yeh, Bosen You, Jialin Meng, Philip Chang, Yuanjie Niu, Gonghui Li, Changxue Lu, Yezi Zhu, Emmanuel S. Antonarakis, Jun Luo, Chi-Ping Huang, Wanhai Xu, Chawnshang Chang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e9d6def113e84a60bc881fcbffc3cdfb |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
par: Jie Luo, et autres
Publié: (2019) -
ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
par: Jae Duck Choi, et autres
Publié: (2021) -
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
par: Ayşe Demirci, et autres
Publié: (2021) -
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
par: Shunsuke Tsuzuki, et autres
Publié: (2021) -
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
par: Stephanie I Kim, et autres
Publié: (2021)